Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
|Podcasts|February 3, 2021
Dr. Stephen Williams on costs of surgical treatments for bladder cancer
Author(s)Urology Times staff
Williams discusses a study comparing costs for radical versus partial cystectomy.
Advertisement
In this episode, Stephen B. Williams, MD, MS, discusses findings from a paper published in Urology titled, Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care, for which he served as a study author. Williams is chief of urology and professor of urology and radiology at the University of Texas Medical Branch at Galveston.
Advertisement
Related to this article
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
The agency issued a PDUFA target action date of June 14, 2027.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5